Metabolic fact of 14C-isosorbide 5-mononitrate in humans.
Single oral doses of 20 mg of the carbon-14 labelled form of the antianginal drug isosorbide 5-mononitrate (5-ISMN, Elantan) were essentially completely absorbed and excreted fairly rapidly in the urine. Means of 24, 52, 78, 93 and 96% dose were excreted during 6, 12, 24, 48 and 120 h, respectively. Concentrations of 14C reached peak levels at about 1-2 h when about 86% of the 14C was associated with the parent drug, 5-ISMN (peak mean level 430 ng/ml), and the remainder mainly with the pharmacologically-inactive denitrated product isosorbide. Because the plasma (and urinary) half-life of isosorbide was longer (about 8-9 h) than that of 5-ISMN (about 4.5 h), the proportions of the former in plasma increased relative to the latter. Concentrations of 14C in whole-blood and plasma were similar, implying that 5-ISMN diffused into blood cells. Concentrations of 5-ISMN in saliva and plasma were almost identical, presumably because of the almost negligible plasma protein binding of the drug (less than 5%). At least five metabolites of 5-ISMN were detected in urine - these were isosorbide (about 37% dose), conjugated material (about 25% dose) presumably mainly 5-ISMN-glucuronide, sorbitol (about 7% dose), the parent drug 5-ISMN (about 2% dose) and two unidentified metabolites (about 7 and 4% dose, respectively). The conjugated material was excreted in the urine relatively more rapidly than the denitrated product, isosorbide.
D000328:Adult; D001711:Biotransformation; D002855:Chromatography, Thin Layer; D006801:Humans; D007547:Isosorbide / Q000097:blood / Q000378:metabolism / Q000652:urine; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000652:urine; D008297:Male; D013058:Mass Spectrometry; D012463:Saliva / Q000378:metabolism; D013997:Time Factors
D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate; D007547:Isosorbide